Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Alvin Ezra Davis III, M.D.

TitleProfessor of Pediatrics. Emeritus
InstitutionImmune Disease Institute
DepartmentEmeritus
AddressImmune Disease Institute
800 Huntington Ave
Boston MA 02115

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Mejia P, Davis AE. C1 inhibitor suppresses the endotoxic activity of a wide range of lipopolysaccharides and interacts with live gram-negative bacteria. Shock. 2012 Aug; 38(2):220-5.
    View in: PubMed
  2. Lu F, Fernandes SM, Davis AE. The effect of C1 inhibitor on myocardial ischemia and reperfusion injury. Cardiovasc Pathol. 2013 Jan; 22(1):75-80.
    View in: PubMed
  3. Davis AE, Lu F, Mejia P. C1 inhibitor, a multi-functional serine protease inhibitor. Thromb Haemost. 2010 Nov; 104(5):886-93.
    View in: PubMed
  4. Lu F, Fernandes SM, Davis AE. The role of the complement and contact systems in the dextran sulfate sodium-induced colitis model: the effect of C1 inhibitor in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2010 Jun; 298(6):G878-83.
    View in: PubMed
  5. Lu F, Chauhan AK, Fernandes SM, Walsh MT, Wagner DD, Davis AE. The effect of C1 inhibitor on intestinal ischemia and reperfusion injury. Am J Physiol Gastrointest Liver Physiol. 2008 Nov; 295(5):G1042-9.
    View in: PubMed
  6. Davis AE, Mejia P, Lu F. Biological activities of C1 inhibitor. Mol Immunol. 2008 Oct; 45(16):4057-63.
    View in: PubMed
  7. Davis AE. New treatments addressing the pathophysiology of hereditary angioedema. Clin Mol Allergy. 2008; 6:2.
    View in: PubMed
  8. Davis AE. Hereditary angioedema: a current state-of-the-art review, III: mechanisms of hereditary angioedema. Ann Allergy Asthma Immunol. 2008 Jan; 100(1 Suppl 2):S7-12.
    View in: PubMed
  9. Liu D, Lu F, Qin G, Fernandes SM, Li J, Davis AE. C1 inhibitor-mediated protection from sepsis. J Immunol. 2007 Sep 15; 179(6):3966-72.
    View in: PubMed
  10. Davis AE, Cai S, Liu D. C1 inhibitor: biologic activities that are independent of protease inhibition. Immunobiology. 2007; 212(4-5):313-23.
    View in: PubMed
  11. Davis AE. Mechanism of angioedema in first complement component inhibitor deficiency. Immunol Allergy Clin North Am. 2006 Nov; 26(4):633-51.
    View in: PubMed
  12. Liu D, Cramer CC, Scafidi J, Davis AE. N-linked glycosylation at Asn3 and the positively charged residues within the amino-terminal domain of the c1 inhibitor are required for interaction of the C1 Inhibitor with Salmonella enterica serovar typhimurium lipopolysaccharide and lipid A. Infect Immun. 2005 Aug; 73(8):4478-87.
    View in: PubMed
  13. Cai S, Dole VS, Bergmeier W, Scafidi J, Feng H, Wagner DD, Davis AE. A direct role for C1 inhibitor in regulation of leukocyte adhesion. J Immunol. 2005 May 15; 174(10):6462-6.
    View in: PubMed
  14. Rosen FS, Davis AE. Deficiencies of C1 inhibitor. Best Pract Res Clin Gastroenterol. 2005 Apr; 19(2):251-61.
    View in: PubMed
  15. Davis AE. The pathophysiology of hereditary angioedema. Clin Immunol. 2005 Jan; 114(1):3-9.
    View in: PubMed
  16. Liu D, Zhang D, Scafidi J, Wu X, Cramer CC, Davis AE. C1 inhibitor prevents Gram-negative bacterial lipopolysaccharide-induced vascular permeability. Blood. 2005 Mar 15; 105(6):2350-5.
    View in: PubMed
  17. Agostoni A, Aygören-Pürsün E, Binkley KE, Blanch A, Bork K, Bouillet L, Bucher C, Castaldo AJ, Cicardi M, Davis AE, De Carolis C, Drouet C, Duponchel C, Farkas H, Fáy K, Fekete B, Fischer B, Fontana L, Füst G, Giacomelli R, Gröner A, Hack CE, Harmat G, Jakenfelds J, Juers M, Kalmár L, Kaposi PN, Karádi I, Kitzinger A, Kollár T, Kreuz W, Lakatos P, Longhurst HJ, Lopez-Trascasa M, Martinez-Saguer I, Monnier N, Nagy I, Németh E, Nielsen EW, Nuijens JH, O'grady C, Pappalardo E, Penna V, Perricone C, Perricone R, Rauch U, Roche O, Rusicke E, Späth PJ, Szendei G, Takács E, Tordai A, Truedsson L, Varga L, Visy B, Williams K, Zanichelli A, Zingale L. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004 Sep; 114(3 Suppl):S51-131.
    View in: PubMed
  18. Davis AE. Biological effects of C1 inhibitor. Drug News Perspect. 2004 Sep; 17(7):439-46.
    View in: PubMed
  19. Bowen T, Cicardi M, Farkas H, Bork K, Kreuz W, Zingale L, Varga L, Martinez-Saguer I, Aygören-Pürsün E, Binkley K, Zuraw B, Davis A, Hebert J, Ritchie B, Burnham J, Castaldo A, Menendez A, Nagy I, Harmat G, Bucher C, Lacuesta G, Issekutz A, Warrington R, Yang W, Dean J, Kanani A, Stark D, McCusker C, Wagner E, Rivard GE, Leith E, Tsai E, MacSween M, Lyanga J, Serushago B, Leznoff A, Waserman S, de Serres J. Canadian 2003 International Consensus Algorithm For the Diagnosis, Therapy, and Management of Hereditary Angioedema. J Allergy Clin Immunol. 2004 Sep; 114(3):629-37.
    View in: PubMed
  20. Liu D, Gu X, Scafidi J, Davis AE. N-linked glycosylation is required for c1 inhibitor-mediated protection from endotoxin shock in mice. Infect Immun. 2004 Apr; 72(4):1946-55.
    View in: PubMed
  21. Davis AE, Cai S, Liu D. The biological role of the C1 inhibitor in regulation of vascular permeability and modulation of inflammation. Adv Immunol. 2004; 82:331-63.
    View in: PubMed
  22. Davis AE. The pathogenesis of hereditary angioedema. Transfus Apher Sci. 2003 Dec; 29(3):195-203.
    View in: PubMed
  23. Binkley KE, Davis AE. Estrogen-dependent inherited angioedema. Transfus Apher Sci. 2003 Dec; 29(3):215-9.
    View in: PubMed
  24. Cai S, Davis AE. Complement regulatory protein C1 inhibitor binds to selectins and interferes with endothelial-leukocyte adhesion. J Immunol. 2003 Nov 1; 171(9):4786-91.
    View in: PubMed
  25. Han Lee ED, Pappalardo E, Scafidi J, Davis AE. Approaches toward reversal of increased vascular permeability in C1 inhibitor deficient mice. Immunol Lett. 2003 Oct 31; 89(2-3):155-60.
    View in: PubMed
  26. Liu D, Cai S, Gu X, Scafidi J, Wu X, Davis AE. C1 inhibitor prevents endotoxin shock via a direct interaction with lipopolysaccharide. J Immunol. 2003 Sep 1; 171(5):2594-601.
    View in: PubMed
  27. Liu D, Scafidi J, Prada AE, Zahedi K, Davis AE. Nuclear phosphatases and the proteasome in suppression of STAT1 activity in hepatocytes. Biochem Biophys Res Commun. 2002 Dec 13; 299(4):574-80.
    View in: PubMed
  28. Welch TR, Frenzke M, Witte D, Davis AE. C5a is important in the tubulointerstitial component of experimental immune complex glomerulonephritis. Clin Exp Immunol. 2002 Oct; 130(1):43-8.
    View in: PubMed
  29. Zahedi K, Prada AE, Mulligan A, Prada JA, Davis AE. Normal transcription of the C1 inhibitor gene is dependent upon a polypurine-polypyrimidine region within the promoter. Inflammation. 2002 Aug; 26(4):183-91.
    View in: PubMed
  30. Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis AE. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest. 2002 Apr; 109(8):1057-63.
    View in: PubMed
  31. Zahedi R, MacFarlane RC, Wisnieski JJ, Davis AE. C1 inhibitor: analysis of the role of amino acid residues within the reactive center loop in target protease recognition. J Immunol. 2001 Aug 1; 167(3):1500-6.
    View in: PubMed
  32. Zahedi R, Braun M, Wetsel RA, Ault BH, Khan A, Welch TR, Frenzke M, Davis AE. The C5a receptor is expressed by human renal proximal tubular epithelial cells. Clin Exp Immunol. 2000 Aug; 121(2):226-33.
    View in: PubMed
  33. Zahedi K, Bissler JJ, Prada AE, Prada JA, Davis AE. The promoter of the C1 inhibitor gene contains a polypurine.polypyrimidine segment that enhances transcriptional activity. J Immunol. 1999 Jun 15; 162(12):7249-55.
    View in: PubMed
  34. Braun M, Davis AE. Cultured human glomerular mesangial cells express the C5a receptor. Kidney Int. 1998 Nov; 54(5):1542-9.
    View in: PubMed
  35. Prada AE, Zahedi K, Davis AE. Regulation of C1 inhibitor synthesis. Immunobiology. 1998 Aug; 199(2):377-88.
    View in: PubMed
  36. Zahedi K, Prada AE, Prada JA, Davis AE. Characterization of the IFN-gamma-responsive element in the 5' flanking region of the C1 inhibitor gene. J Immunol. 1997 Dec 15; 159(12):6091-6.
    View in: PubMed
  37. Zahedi R, Wisnieski J, Davis AE. Role of the P2 residue of complement 1 inhibitor (Ala443) in determination of target protease specificity: inhibition of complement and contact system proteases. J Immunol. 1997 Jul 15; 159(2):983-8.
    View in: PubMed
  38. Bissler JJ, Aulak KS, Donaldson VH, Rosen FS, Cicardi M, Harrison RA, Davis AE. Molecular defects in hereditary angioneurotic edema. Proc Assoc Am Physicians. 1997 Mar; 109(2):164-73.
    View in: PubMed
  39. Davis AE. C1 inhibitor. Functional analysis of naturally-occurring mutant proteins. Adv Exp Med Biol. 1997; 425:185-94.
    View in: PubMed
  40. Donaldson VH, Bissler JJ, Welch TR, Burton MF, Davis AE. Antibody to C1-inhibitor in a patient receiving C1-inhibitor infusions for treatment of hereditary angioneurotic edema with systemic lupus erythematosus reacts with a normal allotype of residue 458 of C1-inhibitor. J Lab Clin Med. 1996 Oct; 128(4):438-43.
    View in: PubMed
  41. Zahedi R, Aulak KS, Eldering E, Davis AE. Characterization of C1 inhibitor-Ta. A dysfunctional C1INH with deletion of lysine 251. J Biol Chem. 1996 Sep 27; 271(39):24307-12.
    View in: PubMed
  42. Malek R, Aulak KS, Davis AE. The catabolism of intact, reactive centre-cleaved and proteinase-complexed C1 inhibitor in the guinea pig. Clin Exp Immunol. 1996 Jul; 105(1):191-7.
    View in: PubMed
  43. Ernst SC, Circolo A, Davis AE, Gheesling-Mullis K, Fliesler M, Strunk RC. Impaired production of both normal and mutant C1 inhibitor proteins in type I hereditary angioedema with a duplication in exon 8. J Immunol. 1996 Jul 1; 157(1):405-10.
    View in: PubMed
  44. Donaldson VH, Wagner CJ, Davis AE. An autoantibody to C1-inhibitor recognizes the reactive center of the inhibitor. J Lab Clin Med. 1996 Feb; 127(2):229-32.
    View in: PubMed
  45. Zahedi R, Bissler JJ, Davis AE, Andreadis C, Wisnieski JJ. Unique C1 inhibitor dysfunction in a kindred without angioedema. II. Identification of an Ala443-->Val substitution and functional analysis of the recombinant mutant protein. J Clin Invest. 1995 Mar; 95(3):1299-305.
    View in: PubMed
  46. Schurman SJ, McAdams AJ, Beischel L, Davis AE, Welch TR. C3-independent glomerulonephritis in guinea pigs: dependence upon primary humoral response. Clin Immunol Immunopathol. 1995 Jan; 74(1):51-8.
    View in: PubMed
  47. Coutinho M, Aulak KS, Davis AE. Functional analysis of the serpin domain of C1 inhibitor. J Immunol. 1994 Oct 15; 153(8):3648-54.
    View in: PubMed
  48. Bissler JJ, Cicardi M, Donaldson VH, Gatenby PA, Rosen FS, Sheffer AL, Davis AE. A cluster of mutations within a short triplet repeat in the C1 inhibitor gene. Proc Natl Acad Sci U S A. 1994 Sep 27; 91(20):9622-5.
    View in: PubMed
  49. Mandle R, Baron C, Roux E, Sundel R, Gelfand J, Aulak K, Davis AE, Rosen FS, Bing DH. Acquired C1 inhibitor deficiency as a result of an autoantibody to the reactive center region of C1 inhibitor. J Immunol. 1994 May 1; 152(9):4680-5.
    View in: PubMed
  50. Zahedi K, Prada AE, Davis AE. Transcriptional regulation of the C1 inhibitor gene by gamma-interferon. J Biol Chem. 1994 Apr 1; 269(13):9669-74.
    View in: PubMed
  51. Bissler JJ, Donaldson VH, Davis AE. Contiguous deletion and duplication mutations resulting in type 1 hereditary angioneurotic edema. Hum Genet. 1994 Mar; 93(3):265-9.
    View in: PubMed
  52. Shoemaker LR, Schurman SJ, Donaldson VH, Davis AE. Hereditary angioneurotic oedema: characterization of plasma kinin and vascular permeability-enhancing activities. Clin Exp Immunol. 1994 Jan; 95(1):22-8.
    View in: PubMed
  53. Aulak KS, Donaldson VH, Coutinho M, Davis AE. C1-inhibitor: structure/function and biologic role. Behring Inst Mitt. 1993 Dec; (93):204-13.
    View in: PubMed
  54. Davis AE, Bissler JJ, Cicardi M. Mutations in the C1 inhibitor gene that result in hereditary angioneurotic edema. Behring Inst Mitt. 1993 Dec; (93):313-20.
    View in: PubMed
  55. Zahedi K, Prada AE, Davis AE. Structure and regulation of the C1 inhibitor gene. Behring Inst Mitt. 1993 Dec; (93):115-9.
    View in: PubMed
  56. Aulak KS, Eldering E, Hack CE, Lubbers YP, Harrison RA, Mast A, Cicardi M, Davis AE. A hinge region mutation in C1-inhibitor (Ala436-->Thr) results in nonsubstrate-like behavior and in polymerization of the molecule. J Biol Chem. 1993 Aug 25; 268(24):18088-94.
    View in: PubMed
  57. Aulak KS, Davis AE, Donaldson VH, Harrison RA. Chymotrypsin inhibitory activity of normal C1-inhibitor and a P1 Arg to His mutant: evidence for the presence of overlapping reactive centers. Protein Sci. 1993 May; 2(5):727-32.
    View in: PubMed
  58. Davis AE, Aulak KS, Zahedi K, Bissler JJ, Harrison RA. C1 inhibitor. Methods Enzymol. 1993; 223:97-120.
    View in: PubMed
  59. Coutinho M, Zahedi K, Whitehead AS, Davis AE. C5 deficiency in A/J mice is not associated with resistance to the development of secondary amyloidosis. Eur J Immunogenet. 1992 Dec; 19(6):419-23.
    View in: PubMed
  60. Davis AE, Patterson F, Crouch R. The effect of therapeutic drugs used in inflammatory bowel disease on the incidence and growth of colonic cancer in the dimethylhydrazine rat model. Br J Cancer. 1992 Nov; 66(5):777-80.
    View in: PubMed
  61. Davis AE, Aulak K, Parad RB, Stecklein HP, Eldering E, Hack CE, Kramer J, Strunk RC, Bissler J, Rosen FS. C1 inhibitor hinge region mutations produce dysfunction by different mechanisms. Nat Genet. 1992 Aug; 1(5):354-8.
    View in: PubMed
  62. Frangi D, Aulak KS, Cicardi M, Harrison RA, Davis AE. A dysfunctional C1 inhibitor protein with a new reactive center mutation (Arg-444-->Leu). FEBS Lett. 1992 Apr 13; 301(1):34-6.
    View in: PubMed
  63. Shohet JM, Bergamaschini L, Davis AE, Carroll MC. Localization of the human complement component C3 binding site on the IgG heavy chain. J Biol Chem. 1991 Oct 5; 266(28):18520-4.
    View in: PubMed
  64. Frangi D, Cicardi M, Sica A, Colotta F, Agostoni A, Davis AE. Nonsense mutations affect C1 inhibitor messenger RNA levels in patients with type I hereditary angioneurotic edema. J Clin Invest. 1991 Sep; 88(3):755-9.
    View in: PubMed
  65. Kramer J, Katz Y, Rosen FS, Davis AE, Strunk RC. Synthesis of C1 inhibitor in fibroblasts from patients with type I and type II hereditary angioneurotic edema. J Clin Invest. 1991 May; 87(5):1614-20.
    View in: PubMed
  66. Ariga T, Carter PE, Davis AE. Recombinations between Alu repeat sequences that result in partial deletions within the C1 inhibitor gene. Genomics. 1990 Dec; 8(4):607-13.
    View in: PubMed
  67. Parad RB, Kramer J, Strunk RC, Rosen FS, Davis AE. Dysfunctional C1 inhibitor Ta: deletion of Lys-251 results in acquisition of an N-glycosylation site. Proc Natl Acad Sci U S A. 1990 Sep; 87(17):6786-90.
    View in: PubMed
  68. Levy NJ, Ramesh N, Cicardi M, Harrison RA, Davis AE. Type II hereditary angioneurotic edema that may result from a single nucleotide change in the codon for alanine-436 in the C1 inhibitor gene. Proc Natl Acad Sci U S A. 1990 Jan; 87(1):265-8.
    View in: PubMed
  69. Davis AE. Structure and function of C1 inhibitor. Behring Inst Mitt. 1989 Jul; (84):142-50.
    View in: PubMed
  70. Ariga T, Igarashi T, Ramesh N, Parad R, Cicardi M, Davis AE. Type I C1 inhibitor deficiency with a small messenger RNA resulting from deletion of one exon. J Clin Invest. 1989 Jun; 83(6):1888-93.
    View in: PubMed
  71. Shelley CS, Remold-O'Donnell E, Davis AE, Bruns GA, Rosen FS, Carroll MC, Whitehead AS. Molecular characterization of sialophorin (CD43), the lymphocyte surface sialoglycoprotein defective in Wiskott-Aldrich syndrome. Proc Natl Acad Sci U S A. 1989 Apr; 86(8):2819-23.
    View in: PubMed
  72. Kirchhausen T, Nathanson KL, Matsui W, Vaisberg A, Chow EP, Burne C, Keen JH, Davis AE. Structural and functional division into two domains of the large (100- to 115-kDa) chains of the clathrin-associated protein complex AP-2. Proc Natl Acad Sci U S A. 1989 Apr; 86(8):2612-6.
    View in: PubMed
  73. Cholin S, Gerard NP, Strang CJ, Davis AE. Biologic activity of a C2-derived peptide. Demonstration of a specific interaction with guinea pig lung tissues. J Immunol. 1989 Apr 1; 142(7):2401-4.
    View in: PubMed
  74. Davis AE. Hereditary and acquired deficiencies of C1 inhibitor. Immunodefic Rev. 1989; 1(3):207-26.
    View in: PubMed
  75. Strang CJ, Cholin S, Spragg J, Davis AE, Schneeberger EE, Donaldson VH, Rosen FS. Angioedema induced by a peptide derived from complement component C2. J Exp Med. 1988 Nov 1; 168(5):1685-98.
    View in: PubMed
  76. Cicardi M, Igarashi T, Kim MS, Frangi D, Agostoni A, Davis AE. Restriction fragment length polymorphism of the C1 inhibitor gene in hereditary angioneurotic edema. J Clin Invest. 1987 Dec; 80(6):1640-3.
    View in: PubMed
  77. Cicardi M, Igarashi T, Rosen FS, Davis AE. Molecular basis for the deficiency of complement 1 inhibitor in type I hereditary angioneurotic edema. J Clin Invest. 1987 Mar; 79(3):698-702.
    View in: PubMed
  78. Remold-O'Donnell E, Davis AE, Kenney D, Bhaskar KR, Rosen FS. Purification and chemical composition of gpL115, the human lymphocyte surface sialoglycoprotein that is defective in Wiskott-Aldrich syndrome. J Biol Chem. 1986 Jun 5; 261(16):7526-30.
    View in: PubMed
  79. Davis AE, Whitehead AS, Harrison RA, Dauphinais A, Bruns GA, Cicardi M, Rosen FS. Human inhibitor of the first component of complement, C1: characterization of cDNA clones and localization of the gene to chromosome 11. Proc Natl Acad Sci U S A. 1986 May; 83(10):3161-5.
    View in: PubMed
  80. Davis AE, Zalut C, Rosen FS, Alper CA. Human factor D of the alternative complement pathway. Physicochemical characteristics and N-terminal amino acid sequence. Biochemistry. 1979 Nov 13; 18(23):5082-7.
    View in: PubMed
  81. Davis AE, Gelfand EW, Schur PH, Rosen FS, Alper CA. IgG subclass studies of C3 nephritic factor. Clin Immunol Immunopathol. 1978 Sep; 11(1):98-101.
    View in: PubMed
  82. Einstein LP, Hansen PJ, Ballow M, Davis AE, Davis JS, Alper CA, Rosen FS, Colten HR. Biosynthesis of the third component of complement (C3) in vitro by monocytes from both normal and homozygous C3-deficient humans. J Clin Invest. 1977 Nov; 60(5):963-9.
    View in: PubMed
  83. Davis AE, Davis JS, Rabson AR, Osofsky SG, Colten HR, Rosen FS, Alper CA. Homozygous C3 deficiency: detection of C3 by radioimmunoassay. Clin Immunol Immunopathol. 1977 Nov; 8(3):543-50.
    View in: PubMed
  84. Davis AE, Ziegler JB, Gelfand EW, Rosen FS, Alper CA. Heterogeneity of nephritic factor and its identification as an immunoglobulin. Proc Natl Acad Sci U S A. 1977 Sep; 74(9):3980-3.
    View in: PubMed
  85. Davis AE, Arnaout MA, Alper CA, Rosen FS. Transfer of C3 nephritic factor from mother to fetus. Is C3 nephritic factor IgG? N Engl J Med. 1977 Jul 21; 297(3):144-5.
    View in: PubMed
  86. Alper CA, Davis AE, Rosen FS. Complement and immunologic disease. Arthritis Rheum. 1977 Mar; 20(2 Suppl):449-58.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Davis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
See all (416) concept(s)
_
Co-Authors
See all (15) people
_
Similar People
See all (60) people
_
Physical Neighbors
_